The product is not meant for everyone interested in GLP-1 drugs
At the same time, the delivery is moving from weekly injections to daily pills, with better tolerability, reduced cost, and demonstrated cardiovascular benefit on top of weight loss
Brand Vyvanse either moved to non-preferred Tier 3 or fell off formularies entirely, with some plans requiring prior authorization to cover the brand when a generic is available
Always consult your GP before making changes to prescribed diabetes or weight management treatments
Clinical Insight In clinical trials, weekly injectable Tirzepatide produced A1C reductions up to 2.0% and 1420% weight loss over 72 weeks
Quick answer: why GLP-1 denials happen Insurance plans deny GLP-1 medications for several common reasons: Plan exclusion: the employer or plan does not cover anti-obesity medications at all